Eﬀectiveness of cytoﬂavin in patients with high risk development of cerebrovascular diseases.

Madzhidova, Y. N.; Yusupaliev, Bakhodir; Sharipov, F. R.; Azimova, Nodira; Mukhammadsolikh, Sh. B.

doi:10.30629/0023-2149-2020-98-6-456-460

jour

2020

DOI: 10.30629/0023-2149-2020-98-6-456-460

|View full text |Cite

Eﬀectiveness of cytoﬂavin in patients with high risk development of cerebrovascular diseases.

Y. N. Madzhidova

Bakhodir Yusupaliev²,

F. R. Sharipov³

et al.

Abstract: The aim of the study was to test the screening of the risk of developing cerebrovascular diseases and assess the eﬀectiveness of cytoflavin in patients with a high risk of developing this pathology.In addition to general clinical screening (determination of glucose and cholesterol levels in the blood, control of blood pressure and pulse, determination of body mass index), assessment of neurological status using an outpatient scale for assessing chronic cerebral ischemia A.I. Fedina and assessment of the level … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2023

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients

Putilina,

Teplova

2023

Medicinskij sovet

View full text Add to dashboard Cite

Antidepressants (ADs) are a group of drugs whose action primarily consists of stimulating neurotransmitter systems (dopaminergic, serotonergic and noradrenergic systems). Neurologists prescribe them for the treatment of post-stroke and other depression, chronic pain syndromes, neuropathic pain, panic attacks, correction of post-Covid syndrome, for the prevention of migraines, Parkinson’s disease and neurodegenerative diseases, including Alzheimer’s disease. However, even with appropriate therapy, many people with depressive disorder may experience subsyndromal symptoms and complete remission is short-lived, so there is a need to use other therapeutic approaches. Combining two or more antidepressants may target different neurochemical pathways while increasing the risk of side effects and the development of resistance. Therefore, the search for alternative treatments is urgent, and oxidative stress appears to be an interesting therapeutic target. The combined use of AD and antioxidants may provide an effective and safe approach to enhancing antidepressant effects by synergistically enhancing certain antidepressant activities (eg, enhancing monoamine reuptake inhibition) or by additive pharmacological effects, such as adjusting neurotransmitters and reducing the damaging effects of active agents. forms of oxygen. There are a number of clinical studies to prove the effectiveness of the combined use of antioxidants and antioxidants. In the group of patients receiving a combination of antioxidants and antidepressants/anti-anxiety drugs, there was a better regression of symptoms and severity of depression, which probably indicates the usefulness of adjuvant antioxidant therapy with regular psychotropic treatment. The use of combination drugs in complex therapy with blood pressure seems to be a promising direction and requires further study.

show abstract

Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients

Putilina,

Teplova

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Neuroprotective therapy in chronic cerebrovascular diseases

Ким

Маджидова

Sharipov

2021

РНЖ

View full text Add to dashboard Cite

Introduction. In chronic cerebrovascular diseases (CVD), neuroprotective medications, the effectiveness of which requires further study, are widely used. The effectiveness of Cytoflavinum in patients with chronic CVD was evaluated.Material and methods. The data of 60 patients (35 women and 25 men) with chronic CVD were analyzed. 30 patients, included in the main group (mean age 61 ± 5.87 years old), in addition to basic therapy (antihypertensive, antithrombotic drugs, statins), received Cytoflavinum according to the following scheme: 1 time a day in the morning intravenously 10.0 ml for 10 days, then 2 tablets 2 times a day for 30 days. 30 patients in the comparison group (mean age 59.8 ± 8.7 years old) received only basic therapy. An analysis of patient complaints, neurological status was carried out. Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) were used.Results. In the group of patients taking Cytoflavinum, there was a decrease in the frequency and intensity of headache, dizziness, an increase in MMSE score from 26.32 ± 0.86 to 28.05 ± 1.36 (p ≤ 0.05), in MoCA score from 25.35 ± 0.96 to 27.88 ± 1.13 (p ≤ 0.05), decrease in anxiety score from 8.82 ± 1.31 to 5.2 ± 2.82 (p ≤ 0.05) and decrease in HADS depression score from 8.31 ± 1.85 to 4.6 ± 3.15 (p ≤ 0.05).Conclusion. The inclusion of Cytoflavinum in the treatment regimen for patients with chronic CVD helps to reduce the frequency and intensity of headaches and dizziness, improve cognitive functions, and reduce the level of anxiety and depression.

show abstract

Dynamics of neurocognitive indicators against the background of neuroprotective therapy of vertebrobasilar insufficiency with cerebral venous discirculation symptoms

Kim

Madjidova

Sharipov

2022

A&Ch

Self Cite

View full text Add to dashboard Cite

The aim of the study was to assess the effect of Cytoflavin on the severity of neurocognitive parameters in patients with chronic cerebral ischemia, as well as vertebrobasilar insufficiency with symptoms of cerebral venous circulation. The study involved 60 patients who were divided into two groups. Cytoflavin was prescribed in the treatment group: once per day in the morning, slow intravenous drip of 10.0 ml per 200 ml of 0.9% sodium chloride solution, the duration of the infusion averaged 40–60 minutes for a course of 10 days with the transition to a tablet form — 2 tablets twice per day for 30 days against the background of standard basic therapy (acetylsalicylic acid and antihypertensive drugs). Patients in the comparison group received only basic therapy. The rating scales for headache (visual analogue scale) and asthenia (asthenic state scale) were used to assess the neurological status in addition to the standard clinical and labo ratory examination. It was revealed that the main clinical and neurological manifestations in patients with symptoms of cerebral venous discirculation are headaches (48 (80%) patients) and dizziness (53 (88.3%) patients). The incidence of dizziness increased with the progression of chronic cerebral ischemia, for example, at stage I dizziness occurred in 57% of cases, at stage II — in 78%, and at stage III — in 100%. When conducting a study of the headache severity dynamics on the VAS scale, a decrease in the intensity of headaches by 1.7 times (5.68±0.62 to 3.23±0.56 points, p[1]0.5) was noted in patients who received Cytoflavin, while only a slight decrease in the intensity of pain was noted in patients of the comparison group. In addition, the inclusion of the drug in the therapy regimens for patients with this pathology showed a significant decrease in the frequency of complaints, including specific «venous» complaints, the severity of cephalgic syndrome, as well as asthenic and autonomic disorders, which had a positive effect on the patients’ quality of life. The results obtained make it possible to recommend the inclusion of the drug in the therapy regimens for patients with symptoms of cerebral venous dysfunction.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Eﬀectiveness of cytoﬂavin in patients with high risk development of cerebrovascular diseases.

Cited by 3 publications

References 7 publications

Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients

Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients

Neuroprotective therapy in chronic cerebrovascular diseases

Dynamics of neurocognitive indicators against the background of neuroprotective therapy of vertebrobasilar insufficiency with cerebral venous discirculation symptoms

Contact Info

Product

Resources

About